KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Ionis Pharmaceuticals (IONS) over the last 10 years, with Q3 2025 value amounting to $24.8 million.

  • Ionis Pharmaceuticals' Other Accumulated Expenses rose 1243.94% to $24.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.8 million, marking a year-over-year increase of 1243.94%. This contributed to the annual value of $19.5 million for FY2024, which is 3424.56% down from last year.
  • According to the latest figures from Q3 2025, Ionis Pharmaceuticals' Other Accumulated Expenses is $24.8 million, which was up 1243.94% from $22.8 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' Other Accumulated Expenses' 5-year high stood at $29.6 million during Q4 2023, with a 5-year trough of $9.6 million in Q1 2023.
  • Over the past 5 years, Ionis Pharmaceuticals' median Other Accumulated Expenses value was $18.0 million (recorded in 2024), while the average stood at $17.8 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first tumbled by 6009.53% in 2021, then soared by 14264.63% in 2023.
  • Quarter analysis of 5 years shows Ionis Pharmaceuticals' Other Accumulated Expenses stood at $12.3 million in 2021, then fell by 0.95% to $12.2 million in 2022, then surged by 142.65% to $29.6 million in 2023, then plummeted by 34.25% to $19.5 million in 2024, then grew by 27.44% to $24.8 million in 2025.
  • Its Other Accumulated Expenses stands at $24.8 million for Q3 2025, versus $22.8 million for Q2 2025 and $22.3 million for Q1 2025.